Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrintยฎ Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ€“ August 12, Read More

2025-08-22T16:35:25-04:00August 12th, 2025|Press Releases|

Agendia’s FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population

This achievement highlights the remarkable seven-year progression of FLEX Read More

2025-04-17T13:48:18-04:00September 12th, 2024|Press Releases|
Go to Top